Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of luveltamab tazevibulin in FOLR1-positive platinum-resistant epithelial ovarian cancer
MOH_2023-08-06_012750Phase 2Not yet recruiting
- Sponsor
- Sutro Biopharma, Inc.
- Start
- Jul 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of luveltamab tazevibulin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Sutro Biopharma, Inc. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
luveltamab tazevibulin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2023-08-06_012750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-06_012750.